Risk factors for relapse in patients with clinical stage i testicular nonseminomatous germ cell tumors

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Dong, Pei ^a   Liu, Zhuo Wei ^a   Li, Xiang Dong ^a   Li, Yong Hong ^a   Yao, Kai ^a   Wu, Song ^a   Qin, Zi Ke ^a   Han, Hui ^a   Zhou, Fang Jian ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cryptorchidism; Relapse; Surveillance; Testicular cancer; Treatment

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CRYPTORCHISM; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR INVASION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PATHOLOGY; RECURRENT DISEASE; TESTIS TUMOR;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; RECURRENCE; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84873418198     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0494-y     Document Type: Article

References (29)

1. Albers P, Albrecht W, Algaba F, et al. EAU guidelines on testicular cancer: 2011 update. Actas Urol Esp. 2012;36(3):127-45.
2. Choueiri TK, Stephenson AJ, et al. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin N Am. 2007;34(2):137-48.
3. Nguyen CT, Fu AZ, Gilligan TD, et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J Clin Oncol. 2010;28(1):119-25.
4. Sonneveld DJ, Koops HS, Sleijfer DT, et al. Surgery versus surveillance in stage I non-seminoma testicular cancer. Semin Surg Oncol. 1999;17(4):230-9.
5. Nelson JB, Chen RN, Bishoff JT, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 1999;54(6):1064-7.
6. Rassweiler JJ, Scheitlin W, Heidenreich A, et al. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol. 2008;54(5):1004-15.
7. Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002;95(3):520-30.
8. Van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370-8.
9. Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):89-96.
10. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009;7(6):672-93.
11. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol. 1995;13(5):1188-94.
12. Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the german testicular cancer study group trial. J Clin Oncol. 2003;21(8):1505-12.
13. Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol. 2003;21(22):4092-9.
14. Liu ZW, Zhou FJ, Han H, et al. Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors. Chin J Cancer. 2008;27(12):1302-6 (in Chinese).
15. Steiner H, Zangerl F, Stohr B, et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol. 2008;180:1348-52.
16. Hendry WF, Norman A, Nicholls J, et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int. 2000;86(1):89-93.
17. Ye YL, Sun XZ, Zheng FF, et al. Clinical analysis of management of pediatric testicular germ cell tumors. Urology. 2012;79(4):892-7.
18. Weir HK, Kreiger N, Marrett LD. Age at puberty and risk of testicular germ cell cancer (Ontario, Canada). Cancer Causes Control. 1998;9(3):253-8.
19. Fossa SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29(8):963-70.
20. Herrinton LJ, Zhao W, Husson G. Management of cryptorchism and risk of testicular cancer. Am J Epidemiol. 2003;157(7):602-5.
21. McLachlan JA, Newbold RR, Burow ME, et al. From malformations to molecular mechanisms in the male: three decades of research on endocrine disruptors. APMIS. 2001;109(4):263-72.
22. Emmen JMA, McLuskey A, Adham IM, et al. Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology. 2000;141(2):846-9.
23. Nef S, Shipman T, Parada LF. A molecular basis for estrogen induced cryptorchidism. Dev Biol. 2000;224(2):354-61.
24. Bouskine A, Nebout M, Mograbi B, et al. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology. 2008;149(2):565-73.
25. Ferlin A, Garolla A, Bettella A, et al. (2005) Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism. Eur J Endocrinol. 2005;152(3):419-25.
26. Garolla A, Ferlin A, Vinanzi C, et al. Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer. 2005;12(3):645-55.
27. Giwercman A, Lundin KB, Eberhard J, et al. Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage. Eur J Cancer. 2004;40(14):2152-8.
28. Mackillop WJ, Zhang-Salomons J, Groome PA, et al. Socioeconomic status and cancer survival in Ontario. J Clin Oncol. 1997;15(4):1680-9.
29. Hoffman KE, Chen MH, Punglia RS, et al. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008;26(24):3937-42.